Tirzepatide

Also known as: LY3298176

Approved comparator exists

Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.

What this is

A dual GIP/GLP-1 receptor agonist peptide. The active ingredient appears in an FDA-approved product, which establishes that the molecule is well characterised — it says nothing about any individual third-party vial.

Evidence position

Grade A. An FDA-approved comparator containing this active exists. The approved product’s identity, strength, sterility and controls do not transfer to material sourced elsewhere.

What the record does not establish

Published research about a molecule is not a test of any particular vial. Identity, purity, strength and microbiological quality are established by lot-level analytical records tied to a matched sample — not by the literature, and not by the presence of an approved comparator.

Where a lot-level record exists it is published on the evidence page and linked from the product. Where it does not exist, the record says so.

Sources

01
FDA approves new medication for chronic weight managementU.S. Food and Drug Administration
Shows
An approved product using this active exists
Does not show
Does not validate any non-approved vial
02
SURMOUNT-1 phase 3 trialPubMed
Shows
Human interventional data for the approved product
Does not show
Studied the approved presentation, not sourced material
03
FDA concerns with unapproved GLP-1 drugsU.S. Food and Drug Administration
Shows
Regulator position on unapproved GLP-1 products
Does not show
Not compound-specific quality data

External database index

LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE

Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.

PUBCHEM / IDENTITY

CID 166567236

CID: 166567236
Formula: C225H348N48O68
Mass: 4813

Open identity record ↗

PUBMED / FOUND RECORDS

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine / 2025 Jul 3PMID 40353578 / DOI 10.1056/NEJMoa2416394
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.The New England journal of medicine / 2021 Aug 5PMID 34170647 / DOI 10.1056/NEJMoa2107519
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.The New England journal of medicine / 2024 Jul 25PMID 38856224 / DOI 10.1056/NEJMoa2401943
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.JAMA internal medicine / 2024 Sep 1PMID 38976257 / DOI 10.1001/jamainternmed.2024.2525
Tirzepatide: A Systematic Update.International journal of molecular sciences / 2022 Nov 23PMID 36498958 / DOI 10.3390/ijms232314631

CLINICALTRIALS.GOV / FOUND RECORDS

TIRzepatide for the Treatment of Obesity in Patients With Atrial FibrillationRECRUITING / PHASE2 / The Cleveland ClinicNCT06802081 / DIRECT intervention MATCH: Tirzepatide
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related ComorbiditiesCOMPLETED / PHASE3 / Eli Lilly and CompanyNCT05822830 / DIRECT intervention MATCH: Tirzepatide
CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational RegistryNOT_YET_RECRUITING / NO PHASE / JULIO GRANADOS MONTIELNCT07567378 / DIRECT intervention MATCH: Tirzepatide
Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.RECRUITING / PHASE4 / Las Rías Medical CenterNCT07588438 / DIRECT intervention MATCH: Tirzepatide
Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.COMPLETED / NO PHASE / Brigham and Women's HospitalNCT07619508 / DIRECT intervention MATCH: Tirzepatide

Related compounds

RM-MET